(CELC) Celcuity Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CELC) Celcuity Inc. Complete Analysis Pack
Celcuity’s Oncology Business Model, Simplified
Discover how Celcuity Inc. turns its oncology focus into a compelling business model. This concise Business Model Canvas breaks down its key partners, value proposition, revenue logic, and strategic priorities in a clear, actionable format. Download the full version to get the complete picture and sharpen your analysis.
Partnerships
Pfizer licensing agreement
Celcuity secured development and commercialization rights to gedatolisib from Pfizer, and the asset remains its lead program in Phase 3 development. That license underpins clinical work, FDA planning, and future launch execution for a drug aimed at HR+/HER2- breast cancer.
Clinical trial sites
Celcuity Inc. relies on U.S. oncology trial centers to enroll breast and ovarian cancer patients for its CELsignia and gedatolisib programs, which are both tied to late-stage clinical evidence. These sites are essential for feasibility, recruitment, and endpoint collection, since oncology trials often need fast enrollment and clean patient follow-up to support regulatory-grade data.
Contract research organizations
Celcuity Inc. can use contract research organizations to manage study operations, site monitoring, and data handling, which helps scale multi-site trials without adding the same fixed headcount. This matters while Celcuity advances late-stage work like VIKTORIA-1, where CRO support can keep enrollment and trial execution moving while preserving cash for R&D.
Diagnostic and pathology laboratories
CELsignia needs live tumor cells and lab-based testing, so diagnostic and pathology laboratories are the key intake point for fresh biopsies and the main check on assay quality. These partners help keep samples viable, support validation and reproducibility, and make the workflow workable across clinic-to-lab handoffs.
- Move fresh specimens fast
- Protect live-cell viability
- Support CLIA/CAP-style testing
- Improve assay reproducibility
Academic oncology and biomarker collaborators
Academic oncology and biomarker collaborators help Celcuity Inc. turn lab signals into clinical proof. They support interpretation of HER2, c-Met, and PI3K readouts, which strengthens its translational science, publication record, and trial credibility as the company advances CELC-G-201 and other biomarker-led studies.
- Validates biomarker readouts
- Improves trial interpretation
- Builds publication credibility
Celcuity’s Phase 3 Push Hinges on Pfizer and Trial Partners
Celcuity Inc. depends on Pfizer for gedatolisib rights, and that license is the core external link behind its Phase 3 breast cancer push. It also relies on oncology trial sites, CROs, pathology labs, and academic biomarker partners to recruit patients, run studies, and validate CELsignia and translational readouts.
| Partner | Role |
|---|---|
| Pfizer | Gedatolisib rights |
| Trial sites | Enroll patients |
| CROs | Run studies |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas mapping Celcuity’s oncology diagnostics and therapeutics strategy for investors and analysts.
Customizable Excel Spreadsheet
Quickly spot how Celcuity Inc. eases unmet oncology needs with a clear, one-page business snapshot.
Reference Sources
Provides a clear source trail for Celcuity Inc. claims, boosting credibility and helping investors verify assumptions fast.
Activities
CELsignia assay development
Celcuity’s CELsignia assay development refines its live tumor cell platform to measure cellular dysfunction in patient samples, with assay design, validation, and lab workflow optimization at the core. This work supports Celcuity’s precision oncology pipeline and clinical readout quality.
Gedatolisib clinical development
Celcuity Inc. centers Key Activities on gedatolisib clinical development for advanced or metastatic HR-positive, HER2-negative breast cancer, including study design, patient enrollment, and dose and efficacy review. The company’s Phase 3 VIKTORIA-1 program is the main value driver for the pipeline, because late-stage data will shape future approval and commercialization risk.
Biomarker and signaling analysis
Celcuity measures 3 key tumor signals — HER2, c-Met, and PI3K pathway activity — to link diagnostics directly to treatment choice. This biomarker readout helps match therapy to disease biology, so each test result can guide a more targeted drug selection.
Regulatory and quality operations
Celcuity’s regulatory and quality operations cover IND/clinical submissions, GxP quality systems, and traceable documentation for both diagnostics and drug programs. In FDA terms, that means keeping lab and trial work audit-ready across 2 regulated paths, which lowers approval risk and speeds commercialization.
- Supports lab and clinical compliance
- Reduces filing and inspection risk
- Builds launch-ready documentation
Scientific data generation and publication
Celcuity Inc. builds translational and clinical datasets from patient tumor samples to show mechanism, response signals, and assay utility; its published and presented data also help build clinician and investor awareness. This matters because the company is still pre-commercial and has focused its 2025-2026 spend on R&D rather than product sales.
- Patient tumor data support assay validation
- Publications help de-risk the science
- Presentations widen clinician reach
Celcuity Advances Diagnostics and Phase 3 Breast Cancer Trial
Celcuity Inc. focuses on 2 regulated tracks: CELsignia assay development for live tumor testing and gedatolisib Phase 3 VIKTORIA-1 work in HR-positive, HER2-negative breast cancer. It also tracks 3 tumor signals, HER2, c-Met, and PI3K, to link diagnostics with treatment choice.
| Key Activity | Data |
|---|---|
| Programs | 2 |
| Biomarkers | 3 |
| Lead trial | Phase 3 |
Full Document Unlocks After Purchase
Business Model Canvas
The Celcuity Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a sample or mockup—this is a direct view of the final file, with the same structure, content, and formatting. Once you complete your order, you’ll get full access to the same ready-to-use document for editing, presenting, or sharing.
Resources
CELsignia platform
CELsignia is Celcuity Inc.'s core diagnostic platform, and it tests live tumor cells to spot pathway dysfunction that can guide treatment. It sits at the center of Celcuity Inc.'s precision oncology model, which in 2025/2026 supports development across solid-tumor programs and a lead asset with late-stage clinical data.
Gedatolisib rights from Pfizer
Celcuity holds licensed development and commercialization rights to gedatolisib from Pfizer, making it its lead therapeutic resource. The asset anchors Celcuity’s pipeline in HR+/HER2- advanced breast cancer, including the VIKTORIA-1 program in PIK3CA wild-type disease, a defined patient group with clear commercial focus.
Proprietary tumor-cell assay methods
Celcuity Inc.’s proprietary live tumor-cell handling and assay methods are a core resource behind the CELsignia platform. Because these methods depend on Celcuity’s know-how and are hard to copy, they help protect the platform’s differentiation and support repeatable testing on patient-derived tumor cells.
Clinical and biomarker datasets
Celcuity Inc.'s clinical and biomarker datasets are a key resource because patient-derived data can validate tumor biology, narrow indication selection, and measure response patterns across trials. In practice, this kind of evidence supports Celcuity Inc.'s biomarker strategy by linking real patient outcomes to target selection and future trial design.
- Validates diagnostic and therapeutic targets
- Improves indication selection
- Tracks response and resistance signals
- Refines future biomarker strategy
Scientific team and Minneapolis headquarters
Celcuity, founded in 2011 and based in Minneapolis, Minnesota, relies on its scientific and operational team as a core execution resource for research, development, and corporate work. This in-house capability supports its oncology pipeline and day-to-day company functions.
- Founded in 2011
- Headquartered in Minneapolis, Minnesota
- Scientific staff drive R&D execution
- Operational staff support corporate functions
Celcuity’s Core Assets Power Late-Stage Cancer Development
Celcuity Inc.’s key resources are its CELsignia platform, licensed rights to gedatolisib, proprietary live tumor-cell assay know-how, and clinical/biomarker data. Founded in 2011 and based in Minneapolis, Minnesota, it uses these assets to support late-stage oncology development, including VIKTORIA-1 in HR+/HER2- breast cancer.
| Resource | Use |
|---|---|
| CELsignia | Live tumor testing |
| Gedatolisib | Lead therapeutic asset |
| 2011 / Minneapolis | Core team base |
Value Propositions
Live tumor cell precision profiling
CELsignia profiles live tumor cells, not just static biomarkers, to expose the cancer-specific signaling defect that is driving growth. In Celcuity Inc.'s 223-patient Phase 3 VIKTORIA-1 study, this live-cell readout is meant to improve therapy matching by aligning treatment with the tumor’s actual biology, not only its marker profile.
Targeted therapy selection support
Celcuity Inc.’s platform helps match patients to the most fitting targeted intervention, which can cut trial-and-error dosing in oncology. That matters most in complex, mixed tumors, where about 70% of breast cancers are HR+/HER2- and treatment choice can shift fast.
HER2, c-Met, and PI3K pathway readouts
CELsignia MP measures 3 signaling readouts—HER2, c-Met, and PI3K—in breast and ovarian tumor cells, giving a direct functional view of pathway activity. That matters in targeted oncology, where HER2 drives about 15%-20% of breast cancers and c-Met and PI3K are linked to resistance and tumor growth.
HR-positive, HER2-negative breast cancer focus
Celcuity Inc.'s gedatolisib targets advanced or metastatic HR-positive, HER2-negative breast cancer, a major group that is about 70% of all breast cancers and still has high unmet need after endocrine resistance. This focus narrows trial design to a clear patient set and addresses a large market with a U.S. breast cancer burden of about 310,720 new cases in 2024.
- Large, defined patient pool
- High unmet need after resistance
- Clearer trial and launch focus
Paired diagnostic and therapeutic model
Celcuity Inc. links 1 diagnostic platform, CELsignia, with 1 drug-development program, led by gedatolisib, to build a test-and-treat model. That pairing can strengthen evidence generation by matching patients to therapy earlier and can help the Company stand out from drug-only peers.
- 1 test platform plus 1 therapy program
- Linked diagnosis and treatment
- Sharper patient selection and data
- Clearer commercial differentiation
Celcuity’s Test-and-Treat Model Targets a Huge Breast Cancer Need
Celcuity Inc. offers a test-and-treat model: CELsignia reads live tumor signaling to guide targeted therapy, while gedatolisib targets a large HR+/HER2- breast cancer pool with high resistance need. In VIKTORIA-1, the Company enrolled 223 patients, and the U.S. saw about 310,720 new breast cancer cases in 2024.
| Value prop | Data point |
|---|---|
| Live-cell profiling | 223-patient Phase 3 VIKTORIA-1 |
| Large market | ~310,720 U.S. cases in 2024 |
Customer Relationships
Clinical collaboration model
Celcuity’s clinical collaboration model ties the company closely to oncologists, investigators, and trial sites, where trust and protocol support drive enrollment and data quality. These are highly technical, data-led relationships, so shared clinical goals matter more than volume.
Medical affairs engagement
In FY2025, Celcuity Inc. stayed pre-revenue, so medical affairs is the main link to clinicians. That matters in precision oncology, where assay results need expert explanation and the therapeutic rationale must be clear for every case.
This support helps doctors read biomarker data, judge patient fit, and use CELC-01 and related clinical evidence with confidence.
Trial site support
Celcuity’s trial-site support keeps clinical sites aligned on enrollment, sample handling, and protocol steps, which matters in a Phase 3 study like VIKTORIA-1, enrolling about 400 patients. Strong site ties help speed recruitment and lift data quality, cutting avoidable site rework.
Lab and diagnostic partner service
Celcuity Inc.’s lab and diagnostic partner service depends on clear workflows, steady assay performance, and fast technical support. In FY2025, Celcuity remained a clinical-stage company with no product revenue, so result reliability and turnaround time matter most for keeping lab partners engaged.
- Test processing must be consistent.
- Support must keep assay results reliable.
Business development partnership management
Celcuity Inc.'s Pfizer agreement points to a partnership-led customer relationship model, where governance, reporting, and milestone checks keep both sides aligned. These ties matter because they help fund development, share risk, and create the path to broader commercialization scale.
- Pfizer deal = partnership model
- Needs governance and reporting
- Milestones drive funding and execution
- Supports scale and commercialization
Trust and Trial Support Drive Celcuity’s Clinical Relationships
Celcuity Inc.’s customer relationships are mostly clinical and partnership-based: oncologists, trial sites, and lab partners need clear protocol support, fast assay feedback, and trust in CELC-01 data. In FY2025, the Company stayed pre-revenue, so medical affairs and trial operations were the main touchpoints.
| FY2025 signal | Why it matters |
|---|---|
| Pre-revenue | Clinician support is core |
| VIKTORIA-1 ~400 patients | Site alignment drives enrollment |
Channels
Oncology clinical trial network
Celcuity Inc. uses an oncology clinical trial network to reach patients with advanced cancer and to generate the response, safety, and biomarker data that validate its diagnostics and therapeutics. In 2025, this network was central to the Phase 3 VIKTORIA-1 program in HR+/HER2- metastatic breast cancer, where site-level patient data supports regulatory and commercial decisions.
Hospital and pathology lab workflows
Hospital and pathology labs are the operating channel for CELsignia, since tumor tissue must move through clinical lab workflows before live-cell testing can run. In the U.S., the National Cancer Institute projects about 2.0 million new cancer cases a year, so specimen access is a real scale issue.
These lab pathways make CELsignia usable in routine care, not just research, by linking surgery, pathology, and testing in one chain. Celcuity’s model depends on that handoff to keep fresh specimens viable for assay turnaround.
Medical conferences and publications
Medical conferences and peer-reviewed papers are key channels for Celcuity Inc. because oncology uptake is evidence-led; ASCO draws about 40,000 attendees, giving its data direct reach to prescribers and researchers. Publishing trial results also strengthens trust with investors and partners, especially as Celcuity advances gedatolisib in late-stage studies.
Direct business development outreach
Celcuity Inc. can use direct business development outreach to pharma and biotech teams to push licensing, co-development, and commercial talks for its pipeline assets. As a pre-revenue, external-rights model company with 0 marketed products, this channel is key for turning clinical data into partner interest.
- Targets pharma and biotech partners
- Supports licensing and collaboration
- Fits external-rights pipeline strategy
Corporate website and investor communications
Celcuity Inc. uses its corporate website and investor communications to reach shareholders, analysts, and other stakeholders through press releases, SEC filings, and corporate updates. These channels keep the market informed on clinical progress and financing needs, which is key for a development-stage biotech.
In FY2025, this public disclosure base helps support market awareness and access to capital by keeping investors current on trial milestones, cash use, and company strategy.
- Press releases on key milestones
- SEC filings and corporate updates
Celcuity’s FY2025 Channels Powered VIKTORIA-1 and a Strong Cash Position
Celcuity Inc.’s channels are its oncology trial sites, pathology and hospital labs for CELsignia, medical conferences and papers, direct BD outreach, and its website and SEC filings. In FY2025, this mix supported Phase 3 VIKTORIA-1, while Celcuity ended the year with $174.4 million in cash and cash equivalents.
| Channel | FY2025 role |
|---|---|
| Trial sites | Patient enrollment |
| Labs | CELsignia testing |
| Conferences | Data reach |
| Website/filings | Investor updates |
Customer Segments
Patients with advanced or metastatic HR-positive HER2-negative breast cancer
Patients with advanced or metastatic HR-positive HER2-negative breast cancer are Celcuity Inc.'s lead therapeutic segment for gedatolisib. This receptor-defined group makes up about 70% of breast cancers, and the metastatic setting is the main clinical target for the company's pipeline.
Breast cancer oncologists
Breast cancer oncologists are the main gatekeepers for therapy choice and trial enrollment, and their use of CELsignia can drive clinical uptake. The American Cancer Society estimated 316,950 new U.S. invasive breast cancer cases in women in 2025, keeping this group central to treatment decisions.
Ovarian cancer care teams
Ovarian cancer care teams are a key segment for Celcuity Inc. because CELsignia MP is being developed for both ovarian and breast tumor cells. The American Cancer Society estimated about 20,890 new U.S. ovarian cancer cases and 12,730 deaths in 2025, so specialists may use its signaling data to guide treatment planning and research.
Hospitals and clinical laboratories
Hospitals and clinical laboratories are Celcuity Inc.’s operational customers in a specimen-based diagnostics model: they receive, process, or support CELsignia testing, and their lab infrastructure is what makes the assay workable in real care settings.
That matters because specimen workflows depend on existing hospital and lab throughput, quality controls, and turnaround discipline, which ties Celcuity’s test adoption to routine clinical operations, not just sales calls.
- Receive and route patient specimens
- Run or support CELsignia testing
- Provide lab infrastructure and QC
Biopharma and licensing partners
Biopharma and licensing partners are a core Celcuity customer segment because they can fund late-stage development, manage regional or global rights, and support future launch work without adding dilution. For Celcuity, this kind of partner-led model can turn pipeline data into non-dilutive value while keeping more cash focused on its lead oncology program.
- Share trial costs and reduce dilution
- Monetize rights through milestones and royalties
- Extend reach into commercialization
Celcuity’s Core Customers Span Patients, Care Teams, and Biopharma
Celcuity Inc. serves four core customer sets: patients with HR-positive/HER2-negative metastatic breast cancer, whose U.S. pool is anchored by 316,950 new invasive breast cancer cases in women in 2025; oncologists who choose therapy and trial enrollment; ovarian cancer teams, with 20,890 new U.S. cases in 2025; and hospitals, labs, and biopharma partners that run CELsignia, support workflows, or fund development.
| Segment | 2025 signal |
|---|---|
| Breast cancer patients | 316,950 U.S. cases |
| Ovarian cancer patients | 20,890 U.S. cases |
| Care teams and labs | Adoption depends on workflow |
| Biopharma partners | Non-dilutive funding source |
Cost Structure
Clinical trial spending
Clinical trial spending is Celcuity Inc.'s biggest cash cost, covering patient recruitment, site fees, monitoring, and data management. As a clinical-stage biotech, bigger and longer Phase 3 studies push cash burn up fast, and Celcuity’s 2025 filings show R&D still drives most operating spend, led by gedatolisib trials.
Research and development salaries
Celcuity Inc. treats research and development salaries as a fixed operating cost for scientific staff, lab personnel, and clinical operations teams that run both diagnostic and therapeutic programs. In FY2025, this headcount-heavy spend stayed central to cash use because clinical-stage biotech work depends on people more than scale.
Assay development and validation costs
CELsignia and CELsignia MP drive assay development and validation costs through lab work, sample processing, and performance testing, with spend tied to reagents, instrumentation, and technical labor. These costs are central to reproducibility and regulatory confidence, and Celcuity reported R&D as its largest operating expense in FY2025 filings.
Regulatory and quality compliance
Celcuity Inc. must fund documentation, quality systems, and regulatory filings for both lab-developed tests and drug programs, so compliance stays a fixed cost even before sales. In 2025, as a still clinical-stage oncology company, that spend is non-negotiable because FDA and CLIA rules shape every assay, trial, and filing.
- Quality systems never stop.
- Regulatory work supports two tracks.
- Compliance protects trial credibility.
General and administrative overhead
Celcuity’s general and administrative overhead funds corporate management, legal, finance, and its Minneapolis, Minnesota headquarters, and it stays a key cash cost before product revenue starts. In Celcuity’s latest annual filing, the company still operated without product sales, so G&A remains central to keeping the business running.
- Funds management and compliance.
- Supports Minneapolis HQ operations.
- Stays material before revenue.
Celcuity’s FY2025 burn stays R&D-heavy with no product sales yet
Celcuity Inc.'s cost base is still dominated by R&D in FY2025, with gedatolisib trial spend, assay validation, and regulatory work driving cash burn. With no product sales yet, fixed G&A and clinical staff costs stay material, but clinical programs remain the main drain.
| Cost item | FY2025 signal |
|---|---|
| R&D | Largest operating expense |
| Revenue | No product sales |
Revenue Streams
Pfizer milestones and royalties
Celcuity’s gedatolisib license with Pfizer can trigger milestone payments as clinical and regulatory steps are hit, and it can also pay royalties if commercialization succeeds. That fits a standard biotech deal path: upfront value is limited, but upside rises with approval and sales, with future revenue still tied to trial and launch outcomes.
Future gedatolisib product sales
If approved, gedatolisib could become Celcuity Inc.'s main oncology revenue stream, starting with advanced or metastatic HR-positive, HER2-negative breast cancer, a segment that makes up about 70% of breast cancers. In the U.S. alone, breast cancer is expected to top 310,000 new cases in 2024, so success here could support the company’s largest long-term product sales base.
CELsignia test fees
Celcuity can monetize CELsignia through clinical test fees, research-use fees, and assay-processing charges, turning the diagnostic asset into direct cash flow. In FY2025, Celcuity did not report material commercial diagnostic revenue, so this stream is still pre-scale and depends on assay adoption.
Collaborative research payments
Biopharma and academic partners can fund CELsignia or related biomarker studies, paying for assay development, testing, and data generation. For Celcuity Inc., this is a non-dilutive revenue stream tied to study volume and partner demand, and it is common for platform-based biotech companies.
- Partner-funded studies
- Assay and testing fees
- Data generation support
- Non-dilutive cash flow
Licensing and service contracts
Celcuity Inc. can earn non-dilutive cash from licensing and service contracts tied to assay use, development support, and data services, which can help fund R&D before full product sales begin. This matters because Celcuity still needs outside capital to advance its pipeline, so early contract income can reduce dilution pressure.
- Assay access fees can monetize core tech.
- Service work can generate near-term cash.
- Data deals can add pre-commercial income.
Celcuity’s Near-Term Revenue Hinges on Non-Dilutive Contract Cash
Celcuity Inc.'s revenue is still mostly pre-commercial in FY2025: gedatolisib can bring milestone, royalty, and future product sales if approved, while CELsignia and partner studies can add assay and service fees before launch. The main near-term cash path is non-dilutive contract income, not product revenue.
| Revenue stream | FY2025 status |
|---|---|
| Gedatolisib milestones and royalties | Potential, approval-linked |
| Gedatolisib sales | Not yet commercial |
| CELsignia test and assay fees | No material revenue reported |
| Partner-funded studies | Non-dilutive, early stage |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.